The results showed that DMBT1 expression was significantly higher in the PTC+HT group compared to the PTC group; high DMBT1 expression was associated with lower risks of clinical staging, lymph node metastasis, and tumor size; the overall immune activity in the high DMBT1 expression group was greater than in the low expression group; important HLA genes were highly expressed in the high DMBT1 expression group; and there were significant differences in key immune checkpoint genes, including CTLA-4 and IDO1, between high and low DMBT1 expression levels (3). The gene discussed is DMBT1; the disease is metastatic malignant neoplasm in the lymph nodes.